Status: Recruiting
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.
Participants needed: 336
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Verdiva Bio Dev LimitedUpdated: Aug 11, 2026Locations: 1
Eligibility criteria
Male or female assigned at birth, inclusive of all gender identities. [+8]
Have any prior diagnosis of type 1 diabetes mellitus or T2DM, or other forms of... [+5]